News

Article

Top 5 Most-Read Type 1 Diabetes Articles of 2023

Author(s):

Our top-read type 1 diabetes articles of 2023 covered increases in rates of pediatric diabetes early in the COVID-19 pandemic, novel therapies for T1D, and links between patient characteristics and T1D outcomes.

Our top-read type 1 diabetes (T1D) articles of 2023 covered increases in rates of pediatric diabetes early in the COVID-19 pandemic, novel therapies for T1D, and links between patient characteristics and T1D outcomes.

Check out our T1D page for more content.

5. Pediatric Diabetes, DKA Rates Increased During Early COVID-19 Pandemic

The incidence rates of T1D and diabetic ketoacidosis (DKA) were substantially higher among children and adolescents following the start of the COVID-19 pandemic than before. T1D incidence was 1.14 times higher during the first year and 1.27 times higher during the second year of the COVID-19 pandemic, compared with the 12 months before the pandemic, according to a review published in JAMA Network Open. The results emphasize the importance of allocating resources to address an increased demand for pediatric diabetes care.

Read the full article here.

4. VX-880 Shows Promise for Insulin, Glucose Management in T1D in New Data

A stem cell-derived islet cell therapy showed promise as a potential future treatment option for individuals with T1D based on findings from the ongoing VX-880 clinical trial. Based on positive outcomes in parts A and B of the trial, an independent data review committee has recommended advancing to Part C, which will entail administering VX-880 at the full target dosage to patients simultaneously. The findings were presented at the American Diabetes Association 83rd Scientific Sessions.

Read the full article here.

3. Severe Hypoglycemia Requiring Hospitalization Increases Premature Death Risk in People With T1D

The strongest predictor for time to death in individuals with T1D was having 2 or more episodes of severe hypoglycemia that required hospitalization, a study published in Diabetes, Obesity and Metabolism found. Researchers noted that patients who died had a higher body mass index compared with patients who remained alive but also experienced a higher number of episodes. Older patients with T1D were also more likely to die compared with younger patients, even though these groups had similar numbers of severe episodes.

Read the full article here.

2. T1D Linked to Accelerated Brain Aging, Unrelated to Alzheimer Disease

Findings published in JAMA Network Open suggested that individuals with T1D may experience increased brain aging without any early signs of Alzheimer disease-related neurodegeneration, with brain atrophy patterns equivalent to a brain age about 6 years older than their actual age. However, Alzheimer disease regional atrophy was comparable between the study and control groups, and atrophy was mainly observed in the bilateral thalamus and putamen brain regions.

Read the full article here.

1. Being Underweight May Increase All-Cause Mortality Risk in T1D

Research published in the Journal of Obesity & Metabolic Syndrome found that patients with T1D who were underweight showed a higher risk of all-cause mortality compared with those considered “normal” weight. Authors of the review noted a historic lack of research on the relationship between BMI and mortality risk among patients with T1D, making it difficult to consistently manage patients with T1D. The pooled analysis found that a BMI considered underweight was associated with a 3.4 times higher risk of all-cause mortality compared with normal BMI.

Read the full article here.

Related Videos
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Screenshot of an interview with Ruben Mesa, MD
Ruben Mesa, MD
Screenshot of Susan Wescott, RPh, MBA
Screenshot of Stephanie Hsia, PharmD
Screenshot of an interview with Megan Ehret, PharmD
Cesar Davila-Chapa, MD
Daniel Howell, MBBS
Tetyana Kendzerska, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo